Prevención y tratamiento del síndrome coronario agudo

Revista Española de Cardiología Suplementos - Tập 6 - Trang 36G-45G - 2006
Antonio J. Domínguez Franco1, Margarita Pérez Caravante1, Manuel F. Jiménez Navarro1, Eduardo de Teresa Galván1
1Servicio de Cardiología. Hospital Clínico Universitario Virgen de la Victoria. Málaga. España

Tài liệu tham khảo

Fuster, 1999, Acute coronary syndromes: biology, Lancet, 353, S115, 10.1016/S0140-6736(99)90234-9 Ross, 1999, Atherosclerosis-an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Libby, 2001, Current concepts of the pathogenesis of the acute coronary syndromes, Circulation, 104, 365, 10.1161/01.CIR.104.3.365 Vanhoutte, 1995, Endothelium-dependent responses in hipertension, Hipertens Res, 18, 87, 10.1291/hypres.18.87 Schmidt, 1999, Activation of receptor for advance glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis, Circ Res, 84, 489, 10.1161/01.RES.84.5.489 Puranik, 2003, Smoking and endotelial function, Prog Cardiovasc Dis, 45, 443, 10.1053/pcad.2003.YPCAD13 Danesh, 1997, Chronic infections and coronary artery disease: is there a link?, Lancet, 350, 430, 10.1016/S0140-6736(97)03079-1 Luscher, 1996, Lipids and endothelial function:effects of lipid lowering and other therapeutic interventions, Curr Opin Lipidol, 7, 234, 10.1097/00041433-199608000-00010 Hackett, 1988, Pre-existing coronary stenoses in patients with first myocardial infarction are not necessarily severe, Eur Heart J, 9, 1317, 10.1093/oxfordjournals.eurheartj.a062449 Falk, 1995, Coronary plaque disruption, Circulation, 92, 657, 10.1161/01.CIR.92.3.657 Fernández Ortiz, 1994, Characterization of the relative trombogenicity of atherosclerotic plaque components: implications for consequences of plaque rupture, J Am Coll Cardiol, 23, 1562, 10.1016/0735-1097(94)90657-2 Davies, 1993, Risk of thrombosis in human atherosclerotic plaques: role of extracelular lipid, macrophage, and smooth muscular cell content, Br Heart J, 69, 377, 10.1136/hrt.69.5.377 Moreno, 1996, Macrophages, smooth muscular cells, and tissue factor in unestable angina. Implication for cell-mediated thrombogenicity in acute coronary syndromes, Circulation, 94, 3090, 10.1161/01.CIR.94.12.3090 Depre, 1996, Neovascularization in human coronary atherosclerotic lesions, Cathet Cardiovasc Diagn, 39, 215, 10.1002/(SICI)1097-0304(199611)39:3<215::AID-CCD1>3.0.CO;2-H Tenaglia, 1998, Neovascularization atherectomy specimens from patients with unestable angina: implications for pathogenesis os unestable angina, Am Heart J, 135, 10, 10.1016/S0002-8703(98)70336-9 Farb, 1996, Coronary plaque erosion without into a lipid core: a frequent cause of coronary thrombosis in sudden cardiac death, Circulation, 93, 1354, 10.1161/01.CIR.93.7.1354 Burke, 1997, Coronary risk factors ans plaque morphology in men with coronary disease who died suddenly, N Engl J Med, 336, 1276, 10.1056/NEJM199705013361802 Fernández Ortiz, 1999, Fisiopatología de la angina instable. Papel de la rotura y trombosis de la placa aterosclerótica, Rev Esp Cardiol, 52, S3 Toschi, 1997, Tissue factor modilates the thrombogenicity of human atherosclerotic plaques, Circulation, 95, 594, 10.1161/01.CIR.95.3.594 Mallat, 1999, Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thromobogenicity, Circulation, 99, 348, 10.1161/01.CIR.99.3.348 Miranda Guardiola, 1999, Papel de la inflamación en la patogenia y pronóstico de la angina inestable, Rev Esp Cardiol, 52, S13 Zeiher, 1995, Tissue endothelin-1 immunoractivity in the active coronary atherosclerotic plaque. A clue to the mechanism of the increased vasoreactivity of the culprit lesion in unstable angina, Ciculation, 91, 941, 10.1161/01.CIR.91.4.941 Constantinides, 1966, Plaque fissuring in human coronary thrombosis, J Atheroscler Res, 6, 1, 10.1016/S0368-1319(66)80056-X Friedman, 1966, The pathogenesis of a coronary thrombus, Am J Pathol, 48, 19 Kaartinen, 1998, Mast cell infiltration in acute coronary síndromes: implications for plaque rupture, J Am Coll Cardiol, 32, 606, 10.1016/S0735-1097(98)00283-6 Laine, 1999, Association between myocardial infarction and the mast cells in the adventicia of the infarct-relative artery, Circulation, 99, 361, 10.1161/01.CIR.99.3.361 Rajavashisth, 1999, Membrane type I matrix metalloproteinase expression in human atherosclerotic plaques: evidence ogf activation by proinflammatory mediators, Circulation, 99, 3103, 10.1161/01.CIR.99.24.3103 Herman, 2001, Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by trabscriptional profiling, Circulation, 104, 1899, 10.1161/hc4101.097419 Sukhova, 1999, Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atherosclerotic plaques, Circulation, 99, 2503, 10.1161/01.CIR.99.19.2503 Shah, 1998, Role of inflammation and metalloproteinases in plaque disruption and thrombosis, Vasc Med, 3, 199, 10.1177/1358836X9800300304 Kol, 1998, Chlamydial heat shock protein 60 localizes in human atheroma and regulates macrophage tumor necrosis factor-alpha and matrix metalloproteinase expression, Circulation, 98, 300, 10.1161/01.CIR.98.4.300 Mach, 1999, T lymphocytes induce endothelial cell matrix metalloproteinase expression by a CD40L dependent mechanism:implication for tubule formation, Am J Pathol, 154, 229, 10.1016/S0002-9440(10)65269-8 Wallner, 1999, Tenascina C is expressed in macrophage-rich human coronary atherosclerotic plaque, Circulation, 99, 1284, 10.1161/01.CIR.99.10.1284 Malat, 2000, Apoptosis In the vasculature: mechanism and functional importance, Br J Pharmacol, 130, 947, 10.1038/sj.bjp.0703407 Torre, 2003, Clinical use of high sensitive C-reactive protein for the prediction of adverse cardiovascular events, Curr Opin Cardiol, 18, 471, 10.1097/00001573-200311000-00008 Ritchie, 1998, Nuclear factor- B is selectively and markedly activated in humans with unestable angina pectoris, Circulation, 98, 1707, 10.1161/01.CIR.98.17.1707 De Lemos, 2003, Association between plasma levels of monocyte chemo-attractant protein-1 and long term clinical outcomes in patients with acute coronary syndromes, Circulation, 107, 690, 10.1161/01.CIR.0000049742.68848.99 Heeschen, 2003, Soluble CD40 ligand in acute coronary syndromes, N Engl J Med, 348, 1104, 10.1056/NEJMoa022600 MacNeill, 2003, Intravascular modalities for detection of vulnerable plaque. Current status, Arterioscler Thromb Vasc Biol, 23, 1333, 10.1161/01.ATV.0000080948.08888.BF Nishimura, 1990, Intravascular ultrasound imaging: in vitro validation and pathologic correlation, J Am Coll Cardiol, 16, 145, 10.1016/0735-1097(90)90472-2 Potkin, 1990, Coronary artery imaging with intravascular high-frequency ultrasound, Circulation, 81, 1575, 10.1161/01.CIR.81.5.1575 Ueda, 2001, Assesment of plaque vulnerability by angioscopic classification of plaque color, Circulation, 104 Hrynchak, 2000, Optical coherence tomography: an introduction to the technique and its use, Optom Vis Sci, 77, 347, 10.1097/00006324-200007000-00009 Stefanadis, 1999, Termal heterogenicity withim human atherosclerotic coronary arteries detected in vivo: anew method of detection by aplication of a special termography caheter, Circulation, 99, 1965, 10.1161/01.CIR.99.15.1965 Stefanadis, 2001, Increased local temperatura in human coronary atheroscleriotic plaques: an independent predictor of clinical outcome in patients undergoing a percutaneous coronary intervention, J Am Coll Cardiol, 37, 1277, 10.1016/S0735-1097(01)01137-8 Romer, 1998, Histopathology of human coronary atherosclerosis by quantifying its chemical composition witn Raman sprectoscopy, Circulation, 97, 878, 10.1161/01.CIR.97.9.878 Schaar, 2003, Characterizing vulnerable plaque features with intravascular elastography, Circulation, 108, 2636, 10.1161/01.CIR.0000097067.96619.1F Schaar, 2004, incidence of high-strain patterns in human coronary areteries assessment with three-dimensional intravascular palpography and correlation with clinical presentation, Circulation, 109, 2716, 10.1161/01.CIR.0000131887.65955.3B Schneiderman, 2003, Vulnerable plaque diagnosis by a self-contained intravascular magnetic resonance imaging probe in ex-vivo human in-situ coronary arteries, J Am Coll Cardiol, 41, A59, 10.1016/S0735-1097(03)80870-7 Fuster, 2005, Atherotrombosis and high risk plaque. Part II: Approaches by non-invasive computed tomographic/magnetic resonance imaging, J Am Coll Cardiol, 46, 1209, 10.1016/j.jacc.2005.03.075 Corti, 2001, Effects of lipid-lowering by simvastatin on human atherosclerotic lesions: a longitudinal study by high resolution, non invasive magnetic resonance imaging, Circulation, 104, 249, 10.1161/01.CIR.104.3.249 Corti, 2005, Effects of aggressive versus conventional lipid lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high resolution magnetic resonance imaging, J Am Coll Cardiol, 46, 106, 10.1016/j.jacc.2005.03.054 Goldstein, 2000, Multiple complex coronary plaques in patients with acute myocardial infarction, N Engl J Med, 343, 915, 10.1056/NEJM200009283431303 Asakura, 2001, Extensive development of vulnerable plaques as a pancoronary process in patient with myocardial infraction: an angioscopy study, J Am Coll Cardiol, 37, 1284, 10.1016/S0735-1097(01)01135-4 Rioufol, 2002, Multiple atherosclerotic plaque rupture in acute coronary syndromes: a three-vessel intravascular intrasound study, Circulation, 106, 804, 10.1161/01.CIR.0000025609.13806.31 Schwartz, 2001, Effects of atrorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: a randomized controlled trial, JAMA, 285, 1711, 10.1001/jama.285.13.1711 1994, Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S), Lancet, 334, 1383 Sacks, 1996, The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterols levels, N Engl J Med, 335, 1001, 10.1056/NEJM199610033351401 1998, Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels, N Engl J Med, 339, 1349, 10.1056/NEJM199811053391902 Cannon, 2004, Intensive versus moderate lipids lowering with statins after acute coronary syndromes, N Engl J Med, 350, 1495, 10.1056/NEJMoa040583 Grundy, 2004, Implications of recents trials for the National Education Program adult Treatment Panel III guidelines, Circulation, 110, 227, 10.1161/01.CIR.0000133317.49796.0E De Lemos, 2004, Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes. Phase Z of the A to Z Trial, JAMA, 292, 1307, 10.1001/jama.292.11.1307 Aikawa, 1998, Lipid lowering by diet reduces matriz metalloproteinase activity and increases collagen content of rabbit atheroma:a potencial mechanicsm of lesion stabilization, Circulation, 97, 2433, 10.1161/01.CIR.97.24.2433 Shah, 2001, High dosis recombinant apolipoprotein A-I (Milano) mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein c deficient mice: potencial implications for acute plaque stabilization, Circulation, 103, 3047, 10.1161/hc2501.092494 Crisby, 2001, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for acute plaque stabilization, Circulation, 103, 926, 10.1161/01.CIR.103.7.926 Jialal, 2001, Effect of hydroxymethyl glutaryl coenzyme A reductasa inhibitor therapy on high sensitive C-reactive protein levels, Circulation, 103, 1933, 10.1161/01.CIR.103.15.1933 Ridker, 2001, Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events, N Engl J Med, 344, 1959, 10.1056/NEJM200106283442601 Biasucci, 1999, Elevated levels of C-reactive protein at discharge in patients with unstable angina predict instability, Circulation, 99, 855, 10.1161/01.CIR.99.7.855 Ridker, 1998, Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels, Circulation, 98, 839, 10.1161/01.CIR.98.9.839 Ridker, 2005, Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density protein cholesterol < 70mg/dl and C-reative protein < 2mg/l. An analysis of the PROVE- IT TIMI-22 Trial, J Am Coll Cardiol, 45, 1644, 10.1016/j.jacc.2005.02.080 Nissen, 2004, Effect of intensive compared with moderate lipidlowering therapy on progression of coronary atherosclerosis: a randomised controlled trial, JAMA, 291, 1071, 10.1001/jama.291.9.1071 Okazaki, 2004, Demostration of the beneficial effect on atherosclerotic by serial volumetric intravascular iltrasound analysis during half a year after coronary event: the ESTABLISH study, Circulation, 110, 1061, 10.1161/01.CIR.0000140261.58966.A4 Hackman, 1996, Levels of soluble cell adhesion in patients with dyslipidemia, Circulation, 93, 1334, 10.1161/01.CIR.93.7.1334 Kalela, 2001, Effect of pravastatin in midly hypercholesterolemic young men on serum matriz metalloproteinases, Am J Cardiol, 88, 173, 10.1016/S0002-9149(01)01616-2 Ridker, 1997, Inflammation, aspirin, and the rIsk of cardiovascular disease in apparently healthy men, N Engl J Med, 326, 973, 10.1056/NEJM199704033361401 Hernández-Presa, 1998, The ACE inhibitor quinapril reduces the arterial expression of NF-κB dependent proinflamatory factors but not of collagen in rabbit model of atherosclerosis, Am J Pathol, 153, 1825, 10.1016/S0002-9440(10)65697-0